XTL 生物製藥
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About XTL 生物製藥
XTL Biopharmaceuticals Ltd. 是一家生物製藥公司，從事收購和開髮用於治療自身免疫性疾病的醫藥產品。其主要候選藥物是 hCDR1，這是一種用於治療系統性紅斑狼瘡和乾燥綜合徵的 II 期準備資產。 XTL Biopharmaceuticals Ltd. 與 Yeda Research and Development Company Limited 就各種適應症的 hCDR1 的研究、開發和商業化簽訂了許可協議。公司前身為Xenograft Technologies Ltd.，1995年7月更名為XTL Biopharmaceuticals Ltd.。XTL Biopharmaceuticals Ltd.成立於1993年，總部位於以色列拉馬特甘。
如何購買 XTL 生物製藥 (XTLB)
登入
1分鐘開戶
僅需1分鐘即可完成帳戶申請和驗證。整個過程完全自助，支援 RockFlow App 和網頁端操作。
充值資金
帳戶驗證完成後，您可以使用首選的支付方式向帳戶充值。
購買 XTLB
透過 RockFlow App 或網頁端搜尋 XTLB，輸入您想要投資的金額，然後點擊確認即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.